Selected article for: "increase morbidity and mortality increase morbidity"

Author: Cabezón, Elena; Arechaga, Ignacio
Title: Drug Weaponry to Fight Against SARS-CoV-2
  • Cord-id: oadhfqqk
  • Document date: 2020_8_25
  • ID: oadhfqqk
    Snippet: The current outbreak of SARS-CoV-2 virus has caused a large increase in mortality and morbidity associated with respiratory diseases. Huge efforts are currently ongoing to develop a vaccine against this virus. However, alternative approaches could be considered in the fight against this disease. Among other strategies, structural-based drug design could be an effective approach to generate specific molecules against SARS-CoV-2, thus reducing viral burden in infected patients. Here, in addition t
    Document: The current outbreak of SARS-CoV-2 virus has caused a large increase in mortality and morbidity associated with respiratory diseases. Huge efforts are currently ongoing to develop a vaccine against this virus. However, alternative approaches could be considered in the fight against this disease. Among other strategies, structural-based drug design could be an effective approach to generate specific molecules against SARS-CoV-2, thus reducing viral burden in infected patients. Here, in addition to this structural approach, we also revise several therapeutic strategies to fight against this viral threat. Furthermore, we report ACE-2 genetic polymorphic variants affecting residues involved in close contacts with SARS-CoV-2 that might be associated to different infection risks. These analyses could provide valuable information to predict the course of the disease.

    Search related documents:
    Co phrase search for related documents
    • accessory gene and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • accessory protein and ace receptor: 1
    • accessory protein and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • ace receptor and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • ace receptor and additional benefit: 1
    • ace receptor and low frequency: 1
    • acute sars cov respiratory syndrome coronavirus and additional benefit: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and additional investigation: 1, 2, 3, 4, 5, 6, 7
    • acute sars cov respiratory syndrome coronavirus and adenosine nucleotide analog: 1, 2
    • acute sars cov respiratory syndrome coronavirus and long process: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and long term infection spread prevent: 1
    • acute sars cov respiratory syndrome coronavirus and low fatality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute sars cov respiratory syndrome coronavirus and low frequency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16